[go: up one dir, main page]

MX2020008881A - Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1. - Google Patents

Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1.

Info

Publication number
MX2020008881A
MX2020008881A MX2020008881A MX2020008881A MX2020008881A MX 2020008881 A MX2020008881 A MX 2020008881A MX 2020008881 A MX2020008881 A MX 2020008881A MX 2020008881 A MX2020008881 A MX 2020008881A MX 2020008881 A MX2020008881 A MX 2020008881A
Authority
MX
Mexico
Prior art keywords
cancer
methods
treatment
chk1 inhibitors
chk1
Prior art date
Application number
MX2020008881A
Other languages
English (en)
Inventor
Christian Andrew Hassig
Bryan William Strouse
Ryan James Hansen
Kenna Lynn Anderes
Snezana Milutinovic
Angie J You
Barbara Klencke
Mark Kowalski
Original Assignee
Sierra Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sierra Oncology Inc filed Critical Sierra Oncology Inc
Publication of MX2020008881A publication Critical patent/MX2020008881A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

En la presente se divulgan métodos de tratamiento para administrar SRA737 como monoterapia o en un tratamiento conjunto útil para tratar pacientes con cáncer.
MX2020008881A 2018-02-26 2019-02-26 Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1. MX2020008881A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862635459P 2018-02-26 2018-02-26
US201862650192P 2018-03-29 2018-03-29
US201862743993P 2018-10-10 2018-10-10
PCT/US2019/019643 WO2019165458A1 (en) 2018-02-26 2019-02-26 Methods of treatment of cancer comprising chk1 inhibitors

Publications (1)

Publication Number Publication Date
MX2020008881A true MX2020008881A (es) 2021-01-08

Family

ID=67687903

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020008881A MX2020008881A (es) 2018-02-26 2019-02-26 Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1.

Country Status (9)

Country Link
US (1) US20200397796A1 (es)
EP (1) EP3758678A4 (es)
JP (2) JP2021514979A (es)
KR (1) KR20200126388A (es)
CN (1) CN112469391A (es)
AU (1) AU2019224164A1 (es)
CA (1) CA3092079A1 (es)
MX (1) MX2020008881A (es)
WO (1) WO2019165458A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018250552B2 (en) 2017-04-10 2022-08-04 Crt Pioneer Fund Lp Chk1 (SRA737)/PARPi combination methods of inhibiting tumor growth
EP3969623A4 (en) * 2019-05-14 2023-06-14 Sierra Oncology, Inc. CANCER TREATMENT METHODS WITH CHK1 INHIBITORS
CA3187760A1 (en) * 2020-08-12 2022-02-17 Boundless Bio, Inc. Replication stress pathway agent compositions and methods for treating cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8481557B2 (en) * 2009-04-11 2013-07-09 Array Biopharma Inc. Method of treatment using checkpoint kinase 1 inhibitors
US9345705B2 (en) * 2011-09-15 2016-05-24 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
KR102635954B1 (ko) * 2012-05-15 2024-02-13 캔써 리서치 테크놀로지 리미티드 5-[[4-[[모르폴린-2-일]메틸아미노]-5-(트리플루오로메틸)-2-피리딜]아미노]피라진-2-카보니트릴 및 그의 치료적 용도
AU2018250552B2 (en) * 2017-04-10 2022-08-04 Crt Pioneer Fund Lp Chk1 (SRA737)/PARPi combination methods of inhibiting tumor growth
US20200157638A1 (en) * 2017-06-01 2020-05-21 Sierra Oncology, Inc. Biomarkers and patient selection strategies

Also Published As

Publication number Publication date
CN112469391A (zh) 2021-03-09
KR20200126388A (ko) 2020-11-06
JP2021514979A (ja) 2021-06-17
AU2019224164A1 (en) 2020-10-01
EP3758678A1 (en) 2021-01-06
JP2024012649A (ja) 2024-01-30
US20200397796A1 (en) 2020-12-24
EP3758678A4 (en) 2022-01-12
WO2019165458A1 (en) 2019-08-29
CA3092079A1 (en) 2019-08-29

Similar Documents

Publication Publication Date Title
ZA202300875B (en) Kat6 inhibitor methods and combinations for cancer treatment
MX2020008906A (es) Compuestos con actividad inductora de ferroptosis y métodos de uso de estos.
MX387885B (es) Inhibidores de ezh2 para tratar linfomas.
MX2020008680A (es) Terapia de combinacion con apilimod y agentes glutamatergicos.
EA201890961A1 (ru) Комбинированная терапия для лечения злокачественных новообразований
PH12017502142A1 (en) Tetrasubstituted aklene compounds and their use
MX2018008426A (es) Combinaciones anti-egfr para tratar tumores.
PH12016502354A1 (en) Pharmaceutical composition
MX2020009773A (es) Terapia de combinacion.
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
CA2908742C (en) Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
MX2017017138A (es) Conjugados homogeneos especificos de sitio con inhibidores de ksp.
EA201890968A1 (ru) Комбинированная терапия для лечения злокачественных новообразований
MX2020006224A (es) Metodos y terapia combinada para el tratamiento del cancer.
MX2020001727A (es) Terapia de combinacion.
PH12017500392A1 (en) Medical treatments based on anamorelin
IL307964A (en) Combined treatment for cancer
ZA202304965B (en) Combination therapy for treating cancer
MX2019013862A (es) Terapia de combinacion.
BR112021006318A2 (pt) terapia de combinação para o tratamento de câncer
EA202191165A1 (ru) Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы
MX2020008881A (es) Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1.
EA202193276A1 (ru) Способы лечения холангиокарциномы
MX2021003160A (es) Combinaciones de inhibidores de tgfbeta e inhibidores de cdk para el tratamiento de cancer de mama.
MX2019003751A (es) Proteina terapeutica.